This study is for subjects that have advanced solid tumors or lymphoma and for whom standard life-prolonging measures are not available.
The purpose of the study is to test the safety of ASTX660 and to see if this drug has an effect on treating cancer. The drug (ASTX660) that will be given in this study is investigational, meaning that it has not yet been approved for treatment of any disease, including cancer. The drug will be given in pill form. The subject may remain in the study for study is estimated to last about 78 months (6.5 years). The exact amount of time the subject will be receiving study drug or be followed up for health information as part of the study depends on how they respond to and tolerate the study drug.

This study is for patients that have been diagnosed with either chronic lymphocytic leukemia, multiple myeloma or both. The purpose of this study is to estimate the proportion of patients with MM and/or CLL who report experiencing financial difficulty in the past 12 months. Participants will complete a telephone survey within 8 weeks after joining the study.

This study is for adult male and females that have been diagnosed with mantle cell lymphoma. The drugs in this study include the combination of bendamustine, obinutuzumab and venetoclax (also called "BOV"). They are each approved for treatment, but is considered investigational (not approved by the FDA), when combined. The purpose of this study is to find out if BOV is effective and safe for the treatment of people with mantle cell lymphoma. Participants can expect to be in this study for approximately 51/2 years.

This study is for adult male and female subjects that have been diagnosed with classical Hodgkin lymphoma (cHL) or peripheral T cell lymphoma (PTCL). The investigational drug in this study is Brentuximab vedotin. The purpose of this study is to test if brentuximab vedotin works to treat cHL and PTCL in people who already got brentuximab vedotin. Participants in this study will visit MUSC at least every 21 days and will continue to be followed every 4 months, until the study is closed.

This study is for subjects that have been diagnosed with mantle cell lymphoma (MCL) and have already received at least one form of treatment. This study will evaluate the effects, good and bad, of the study drugs palbociclib and ibrutinib in your type of cancer. The purpose of this study is to study the effects of an investigational combination of ibrutinib and a drug called palbociclib on MCL. The subject will be in the study for as long as you do not experience any unacceptable side effects and your cancer does not become worse.

This study is for patients that have been diagnosed with chronic lymphocytic leukemia (CLL). The investigational drugs in this study are ibrutinib, obinutuzumab and venetoclax. The purpose of this study is to compare the usual treatment of ibrutinib and obinutuzumab to a combination treatment of ibrutinib and obinutuzumab plus the study drug, venetoclax.